Reference - Detail
| RRC ID | 38546 |
|---|---|
| Author | Fukushi Y, Hazawa M, Takahashi K, Yoshizawa A, Kashiwakura I. |
| Title | Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line. |
| Journal | Invest New Drugs |
| Abstract |
Liquid crystals are the state of matter existing between the liquid and the crystalline phase, and there is a recent surging interest in its biological effects. Our previous study showed that liquid crystal-related compounds (LCRCs), which are precursors of the liquid crystal, enhanced hematopoietic differentiation at a relatively low concentration (Biol Pharm Bull, 32, 2009). However, biological potentials of LCRCs on tumor cells are unclear. In this study, the biological activity of 16 LCRCs to a chronic myelogenous leukemia cell line, K562, was evaluated. As a result, two compounds, 2-(4-butoxyphenyl)-5-(4-hydroxyphenyl)pyrimidine (compound 7) and 2-{4-(4-hexyloxyphenyl)phenyl}-5-hydroxypyrimidine (compound 9) showed marked growth suppression of K562 cells at μM range. These compounds are similar in structure with a core of three aromatic rings including a pyrimidine ring and residues of one alkyl chain and one hydroxide on either side. In addition, only compound 7 induced the activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase, and apoptosis of K562 cells. The contrasting results between compounds 7 and 9 indicate different mechanisms to suppress the cell proliferation between the two compounds. These results suggest the possibility of LCRCs for application as new antitumor drugs. |
| Volume | 29(5) |
| Pages | 827-32 |
| Published | 2011-10-1 |
| DOI | 10.1007/s10637-010-9430-6 |
| PMID | 20422253 |
| MeSH | Antineoplastic Agents / chemistry Antineoplastic Agents / pharmacology* Apoptosis / drug effects* Blotting, Western Cell Cycle / drug effects Cell Proliferation / drug effects Cell Survival / drug effects Drug Screening Assays, Antitumor Humans K562 Cells Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology* Liquid Crystals / chemistry* Signal Transduction / drug effects |
| IF | 3.525 |
| Times Cited | 5 |
| WOS Category | PHARMACOLOGY & PHARMACY ONCOLOGY |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 4 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | |